title: Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
authors: Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
authors: K
authors: K
authors: Vandevyvere
authors: Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
authors: F P
authors: FP
authors: Luyten
authors: Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
authors: P
authors: P
authors: Verschueren
authors: Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
authors: R
authors: R
authors: Lories
authors: Division of Dermatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
authors: S
authors: S
authors: Segaert
authors: Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. Rene.Westhovens@uz.kuleuven.be.
authors: R
authors: R
authors: Westhovens
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab